Skip to Main Content

Podcast Archive

HelixTalk #173 - Balancing Access and Safety: The FDA's Prescription Drug Risk Mitigation Strategy (REMS)

Date posted: October 31, 2023, 6:00 am

In this episode, we will discuss the definition of REMS (Risk Evaluation and Mitigation Strategies), why they exist, the role of FDA in administering REMS, types and examples of REMS, and how they impact pharmacy practice.

HelixTalk #172 - Battle of the Clot Busters: Alteplase vs. Tenecteplase for Acute Ischemic Stroke

Date posted: October 10, 2023, 6:00 am

In this episode, we review the role and indications of thrombolytics in acute ischemic stroke. The efficacy, safety, administration considerations, and cost between alteplase and tenecteplase are compared and contrasted.

HelixTalk #171 - Two Vax’s and a MAB: What’s New in RSV Prevention

Date posted: September 19, 2023, 6:00 am

In this episode, we briefly review RSV (respiratory syncytial virus) infections and focus on new data supporting the use of two different RSV vaccines (Abrysvo and Arvexy) in preventing RSV infections in older adults and in pregnant women.

HelixTalk #170 - Hope and Healing: Overcoming Opioid Use Disorder Through Evidence-Based Therapies

Date posted: August 29, 2023, 6:00 am

In this episode, together with our faculty colleague, Dr. Roberta Dume, PharmD, BCPP, we discuss the pharmacologic options and evidence for the treatment of opioid use disorder (OUD) and how pharmacists play a vital role in assisting patients suffering from opioid use disorder.

HelixTalk #169 - Introducing HelixTalk’s 2023 Drug Superlative Awards!

Date posted: August 8, 2023, 6:00 am

In this episode, we announce the second iteration of the HelixTalk Drug Superlative Awards -- awards given to medications on the market that are outstanding or notorious. In announcing these completely fictitious awards, we review key clinical pearls and pitfalls that every clinician should be aware of with these notable medications.

HelixTalk #168 - Beyond the Controversy: Exploring Efficacy and Safety of Medication Abortion

Date posted: July 18, 2023, 6:00 am

There has been a lot of news about abortion (abortifacient) medications recently. Since the overturn of Roe v. Wade in 2022, individual states passed their own laws restricting access to abortion, this includes access to abortion medications. This clearly impacts the way pharmacists practice. In this episode, we summarize the science behind the two main abortive drugs, mifepristone and misoprostol, and provide a picture of how the access to these medications stand in the United States.

HelixTalk #167 - Beyond One-Size-Fits-All: Unraveling the Genetic Tapestry of CYP2D6 Drug Metabolism

Date posted: June 27, 2023, 6:00 am

In this episode, we review the science behind genetic differences in humans in the CYP2D6 hepatic enzyme responsible for drug metabolism and how these genetic variants can lead to certain drugs being metabolized far too much or far too little, which can cause drug toxicities or a lack of effectiveness.

HelixTalk #166 - Thiazide Throwdown: Hydrochlorothiazide vs. Chlorthalidone - The Ultimate Showdown for Hypertension Management

Date posted: June 6, 2023, 6:00 am

In this episode, we compare hydrochlorothiazide and chlorthalidone, but specifically from a cardiovascular outcomes perspective when used in patients with hypertension.

HelixTalk #165 - QT and the Beast: Managing Medications That Prolong the QT Interval

Date posted: May 16, 2023, 6:00 am

In this episode, we discuss the concerns of QTc prolongation, which can cause a fatal arrhythmia called torsades de pointes (TdP). We cover the difference between QT and QTc, how to interpret a QTc (and when it is inaccurate), common medications that prolong QTc, and how pharmacists can evaluate the risk of QTc/TdP in patients who are receiving QTc-prolonging therapies.

HelixTalk #164 - Breaking Down the Updates: Key Changes and Implications of the 2023 American Diabetes Association Guidelines

Date posted: April 25, 2023, 6:00 am

In this episode, we will discuss the most important updates from the American Diabetes Association’s 2023 Standards of Care in Diabetes.